Aggregation stability of a monoclonal antibody during downstream processing
- PMID: 21448757
- DOI: 10.1007/s11095-011-0416-7
Aggregation stability of a monoclonal antibody during downstream processing
Abstract
Purpose: To study the effect of several operative parameters, particularly pH and salt concentration, on the stability and aggregation kinetics of IgG solutions under the conditions typically encountered in downstream processing.
Methods: The time evolution of the aggregates is analyzed by a combination of dynamic light scattering, size exclusion chromatography (SEC) and field flow fractionation (FFF). Secondary structure changes are monitored by circular dichroism.
Results: For the given antibody, it is found that at pH lower than 4.0 addition of salt induces a reversible aggregation to oligomers accompanied by an increase in the content of the β-sheet structure. The aggregation rate increases monotonically with the salt concentration. Both the SEC and FFF techniques are successfully applied to obtain the oligomer distributions, and their results are consistent. The modified Lumry-Eyring kinetic model can well describe the time evolutions of the oligomers.
Conclusions: For the given antibody, low pH and presence of salt induce conformational changes that are responsible for the reversible aggregation, but in the investigated conditions only small soluble oligomers are formed and oligomer sizes larger than trimer are negligible. For this reason, no accompanied macroscopic changes can be observed.
Similar articles
-
Reversible NaCl-induced aggregation of a monoclonal antibody at low pH: Characterization of aggregates and factors affecting aggregation.Eur J Pharm Biopharm. 2016 Oct;107:310-20. doi: 10.1016/j.ejpb.2016.07.020. Epub 2016 Jul 20. Eur J Pharm Biopharm. 2016. PMID: 27449627
-
Aggregation mechanism of an IgG2 and two IgG1 monoclonal antibodies at low pH: from oligomers to larger aggregates.Pharm Res. 2013 Mar;30(3):641-54. doi: 10.1007/s11095-012-0885-3. Epub 2012 Oct 9. Pharm Res. 2013. PMID: 23054090
-
Conformational and Colloidal Stabilities of Isolated Constant Domains of Human Immunoglobulin G and Their Impact on Antibody Aggregation under Acidic Conditions.Mol Pharm. 2015 May 4;12(5):1443-55. doi: 10.1021/mp500759p. Epub 2015 Apr 23. Mol Pharm. 2015. PMID: 25871775
-
Mass spectrometric analysis of intact human monoclonal antibody aggregates fractionated by size-exclusion chromatography.Pharm Res. 2010 Oct;27(10):2197-204. doi: 10.1007/s11095-010-0224-5. Epub 2010 Aug 3. Pharm Res. 2010. PMID: 20680668 Free PMC article.
-
Role of cosolutes in the aggregation kinetics of monoclonal antibodies.J Phys Chem B. 2014 Oct 16;118(41):11921-30. doi: 10.1021/jp508000w. Epub 2014 Oct 2. J Phys Chem B. 2014. PMID: 25243487
Cited by
-
AlphaScreen-based homogeneous assay using a pair of 25-residue artificial proteins for high-throughput analysis of non-native IgG.Sci Rep. 2017 Sep 29;7(1):12466. doi: 10.1038/s41598-017-12693-w. Sci Rep. 2017. PMID: 28963557 Free PMC article.
-
Spatially Resolved Effects of Protein Freeze-Thawing in a Small-Scale Model Using Monoclonal Antibodies.Pharmaceutics. 2020 Apr 21;12(4):382. doi: 10.3390/pharmaceutics12040382. Pharmaceutics. 2020. PMID: 32326286 Free PMC article.
-
Aggregation Kinetics for IgG1-Based Monoclonal Antibody Therapeutics.AAPS J. 2016 May;18(3):689-702. doi: 10.1208/s12248-016-9887-0. Epub 2016 Feb 22. AAPS J. 2016. PMID: 26902302 Free PMC article.
-
Aggregation and chemical modification of monoclonal antibodies under upstream processing conditions.Pharm Res. 2013 May;30(5):1380-99. doi: 10.1007/s11095-013-0977-8. Epub 2013 Jan 16. Pharm Res. 2013. PMID: 23322133
-
Molecular Chimera in Cancer Drug Discovery: Beyond Antibody Therapy, Designing Grafted Stable Peptides Targeting Cancer.Int J Pept Res Ther. 2025;31(3):38. doi: 10.1007/s10989-025-10690-6. Epub 2025 Feb 17. Int J Pept Res Ther. 2025. PMID: 39974747 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources